For more than 25 years, Takeda has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs in gastroenterology (GI). Takeda prioritises areas of GI associated with high unmet need, such as inflammatory bowel disease, GI acid-related diseases and GI motility disorders.